Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease

Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46. doi: 10.1167/iovs.11-7498.

Abstract

Purpose: Immunization with glatiramer acetate (GA) alleviates the neuropathology associated with glaucoma and Alzheimer's disease (AD) in rodent models. This research was undertaken to screen for molecular factors underlying GA-induced neuroprotective mechanisms in these models of chronic neurodegeneration.

Methods: Gene expression profiles were analyzed in GA-immunized versus nonimmunized elevated-intraocular pressure (IOP) rat models of glaucoma by using whole genome cDNA microarrays and were further validated by quantitative real-time PCR analysis. A gene, prominently upregulated by GA in elevated IOP retina, was further studied in APP(SWE)/PS1(ΔE9)-transgenic (AD-Tg) mice after GA immunization.

Results: Seven days after treatment with GA, numerous genes were regulated in the retinas of rats with elevated IOP. Comprehensive functional classification and DAVID/KEGG enrichment analysis of GA-induced differentially expressed genes revealed annotation terms and pathways involved in neuroprotection, immune responses, cell communication, and regeneration. Specifically, increased mRNA levels of an early growth response (Egr) 1 gene were evident in GA-immunized retinas with elevated IOP. In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization. Nuclear EGR1 in the dentate gyrus colocalized more frequently with doublecortin-positive and Ki67 proliferating neural progenitors in GA-immunized as compared to nonimmunized AD-Tg mice. Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.

Conclusions: This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model. Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / genetics
  • Alzheimer Disease / immunology
  • Animals
  • Chronic Disease
  • Disease Models, Animal
  • Doublecortin Protein
  • Early Growth Response Protein 1 / genetics*
  • Female
  • Gene Expression / drug effects
  • Gene Expression / immunology
  • Glatiramer Acetate
  • Glaucoma / drug therapy*
  • Glaucoma / genetics
  • Glaucoma / immunology
  • Hippocampus / physiology
  • Immunosuppressive Agents / pharmacology*
  • Male
  • Mice
  • Mice, Transgenic
  • Nerve Degeneration / drug therapy
  • Nerve Degeneration / genetics
  • Nerve Degeneration / immunology
  • Neuroprotective Agents / pharmacology
  • Oligonucleotide Array Sequence Analysis
  • Peptides / pharmacology*
  • Rats
  • Rats, Inbred Lew
  • Real-Time Polymerase Chain Reaction

Substances

  • Dcx protein, rat
  • Doublecortin Protein
  • Early Growth Response Protein 1
  • Egr1 protein, mouse
  • Egr1 protein, rat
  • Immunosuppressive Agents
  • Neuroprotective Agents
  • Peptides
  • Glatiramer Acetate